Impella
Payments companies reported to CMS as associated with Impella. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.
By year
Payments reported as associated with Impella, per program year, as reported to CMS.
Who makes it
Specialties most often involved
Where the associated payments went, by the receiving clinician's specialty.
Clinicians most associated with Impella
These are the largest totals companies reported as associated with Impella. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.
| Clinician | Location | Specialty | Associated payments (2023-2025) |
|---|---|---|---|
| Navin Kapur | Baltimore, MD | Cardiovascular Disease | $800,621.01 |
| George Vetrovec | Richmond, VA | Cardiovascular Disease | $782,550.89 |
| William Oneill | Naples, FL | Cardiovascular Disease | $328,700.92 |
| Amir Kaki | Detroit, MI | Interventional Cardiology | $301,603.98 |
| Scott Silvestry | Orlando, FL | Transplant Surgery | $273,510.83 |
| Mark Anderson | Philadelphia, PA | Thoracic Surgery (Cardiothoracic Vascular Surgery) | $221,027.98 |
| Marc Dickstein | New York, NY | Anesthesiology | $196,166.02 |
| Elias Zias | New York, NY | Thoracic Surgery (Cardiothoracic Vascular Surgery) | $190,137.53 |
| Stephen Kidd | Saint Cloud, MN | Interventional Cardiology | $190,034.50 |
| Omid Zad | Orlando, FL | Critical Care Medicine (Internal Medicine) | $189,786.14 |
Prescribed Impella?
See what its makers reported for your doctor. Two steps, private, no account.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.